Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
US9228204B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9228204-B2 |
| Application number | US-201313975004-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 23, 2013 |
| Priority date | Feb 14, 2011 |
| Publication date | Jan 5, 2016 |
| Grant date | Jan 5, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.
Opening claim text (preview).
What is claimed is: 1. A transformation construct for generating induced pluripotent stem (iPS) cells, comprising: an expression vector including a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter, wherein the plurality of reprogramming factors includes OCT3/4, SOX2, and at least one member selected from the group consisting of KLF4, c-Myc, NANOG, and LIN28. 2. The construct of claim 1 , wherein the expression vector is selected from the group consisting of plasmids, viruses, and combinations thereof. 3. The construct of claim 1 , wherein the expression vector is selected from the group consisting of adenoviral vectors, episomal vectors, retroviral vectors, and lentiviral vectors. 4. The construct of claim 1 , wherein the expression vector is an episomal vector. 5. The construct of claim 1 , wherein the plurality of reprogramming factors includes OCT3/4, SOX2, KLF4, and c-Myc. 6. The construct of claim 1 , wherein the plurality of reprogramming factors consists of OCT3/4, SOX2, and KLF4. 7. The construct of claim 1 , wherein the plurality of reprogramming factors includes OCT3/4, SOX2, NANOG, and LIN28. 8. The construct of claim 1 , wherein the expression vector has a sequence that is at least 80% homologous to SEQ ID 72. 9. The construct of claim 1 , wherein the expression vector has a sequence that is at least 95% homologous to SEQ ID 72. 10. The construct of claim 1 , wherein at least one of reprogramming factor is under the control of a CMV promoter. 11. The construct of claim 10 , wherein the CMV promoter is a weak CMV promoter. 12. The construct of claim 1 , wherein the expression vector further includes a reporter sequence under control of a separate promoter.
viral genome or elements thereof as genetic vector · CPC title
Neurons · CPC title
for animal cells · CPC title
Oct-3/4 · CPC title
Sox-2 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.